Pericarditis Market Size, Share, Growth, And Industry Analysis By Type (Acute Pericarditis, Chronic Pericarditis, Recurrent Pericarditis) By Application (Hospitals & Clinics, Medical Institutes, Research Organization) Covid-19 Impact, Latest Trends, Segmentation, Driving Factors, Restraining Factors, Key Industry Players, Regional Insights, and Forecast To 2031

Updated On: 08 July 2024

Pericarditis Market Report Overview

• 
• to learn more about this report

The global pericarditis market size was USD 1960.9 million in 2022 and is expected to reach USD 3141.86 million in 2031, exhibiting a CAGR of 4.5% during the forecast period.

Pericarditis is an inflammation and swelling of the delicate, sac-like tissue around the heart (pericardium). Sharp chest pain is a common symptom of pericarditis. When the inflamed pericardium's layers rub against one another, it results in chest pains. The cause of most pericarditis isn’t known, but viral infections are responsible for 80 to 90% of cases. It typically lasts less than 3 weeks. Treatment for pericarditis will depend on its underlying cause. If you have a bacterial infection, a doctor may prescribe antibiotics.

Aspirin has historically been used as a single medication to treat severe pericarditis. Clinical trials for a dual therapy regimen combining aspirin and colchicine for the treatment of pericarditis are currently being conducted. The data show that combination treatment is advantageous in reducing the incidence of pericarditis recurrence when compared to conventional monotherapy. These elements are probably going to help the global Pericarditis Market for pericarditis medications increase.

COVID-19 Impact: Pericarditis Medication To Assist In Battling COVID-19

The global COVID-19 pandemic has been unprecedented and staggering, with Pericarditis Market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

The effects of the COVID-19 pandemic are already being felt on a global level, the COVID-19 pandemic is a highly contagious viral infection that often shows up as symptoms mostly related to the respiratory system. Many of the symptoms of pericarditis are similar to those of other heart and lung conditions. In hospitalized patients with COVID‐19, pericardial effusion has been prevalent, this resulted into the extended demand for the medication for the acute pericarditis. Although, the outbreak of COVID-19 had a negative impact on several markets, the Pericarditis Market size grew as result of the its impact on treatment of respiratory problems caused by COVID-19.

Latest Trends

"Emerging Cardiovascular Surgery To Positively Impact The Market Growth"

The market growth for pericarditis medications is anticipated to be driven by the increase in the prevalence of cardiovascular illnesses, pericarditis, and developing therapeutics for pericarditis. The World Health Organization's July 2021 update states that cardiovascular illnesses, comprising conditions like coronary heart disease, cerebrovascular disease, rheumatic heart disease, congenital heart disease, and others, are the main cause of mortality worldwide. According to the same source, almost 32% of all fatalities worldwide—or 17.9 million people—were caused by cardiovascular disorders. As pericarditis is frequently linked to cardiac surgeries and heart attacks, the high frequency of cardiovascular diseases and the mortality associated with it are anticipated to propel the market expansion for pericarditis medications.

Pericarditis Market Segmentation

• 
• to learn more about this report

• By Type Analysis

According to type, the market can be segmented into Acute Pericarditis, Chronic Pericarditis, Recurrent Pericarditis. Among these, the Acute Pericarditis is the leading segment by type.

• By Application Analysis

Based on application, the market can be divided into Hospitals & Clinics, Medical Institutes, Research Organization. [mention dominating segment from the link provided]. Note: don’t disclose the % share of the segment.

Driving Factors

Dual Treatment And Advance Surgery To Drive Up The Demand

The patients suffering from Pericarditis, based on test results, patients are given non-steroidal anti-inflammatory drugs (NSAIDs) such aspirin or ibuprofen. Along with NSAIDs, colchicine is advised as a first-line treatment. The different therapeutic options available for sickness treatment may create new chances for the pericarditis medical sector. Due to the advent of biologics, acceptance of dual treatment, and approval of new pharmaceuticals, the Pericarditis Market size for pericarditis medications is anticipated to increase.

Awareness For Pericarditis To Increase Due To Cardiovascular Therapies

Pericarditis is a form of inflammation in the pericardium, the area surrounding the heart Several therapies are emerging for the people suffering from cardiovascular diseases. With the developments in the field of cardiac therapy, there has been an increase in demand for pericarditis medications worldwide. The availability of pericarditis medications is encouraging for the pharmaceutical sector and has been a major driver of market expansion. Regarding the diagnosis and treatment of cardiovascular disorders, there have been significant developments in the healthcare field.

Restraining Factors

"Lack Of Awareness About The Treatment To Impede The Market"

The perception for the diseases such chest pains, fever, weakness, palpitations, and shortness of breath which are symptoms of Pericarditis are taken very lightly. Usually, these symptoms are treated with simple medication. This hampers the Pericarditis Market growth.

Pericarditis Market Regional Insights

• 
• to learn more about this report

"North America To Lead The Market Due To Developed Healthcare Industry"

The North America comprising of U.S., Canada due to the well-developed tertiary healthcare industry is the leading region for Pericarditis Market. The urbanized lifestyle of Europe is resulting in several cardiovascular disease and advanced R&D facility makes it the second leading region for the Pericarditis Market.

Key Industry Players

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by collaborating with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Market Players Profiled

• Pfizer Inc. (U.S.)
• Bayer AG (Germany)
• PerkinElmer Inc. (U.S.)
• Allergen (Ireland)
• Lincoln Pharmaceuticals Ltd. (India)
• Unicure India Pvt. Ltd., (India)
• Zydus Cadila Healthcare Ltd. (India)

Report Coverage

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.